Abstract
A series of 3-methyl-1-alkyl-2-(thiazol-4-yl)benzimidazol-3-ium ionic liquids were prepared synthetically in three steps with high overall isolated yields and their physicochemical and chemical structure were determined using different analysis techniques. The biological application of the synthesized ionic liquids has been evaluated in vitro against a panel of four human cancer cell lines: HT29, MDA-MB 231, K652 and SKBR3 using a MTT colorimetric assay. It can be concluded that among all of them compound 4fy containing C18 alkyl chain and BF4− as counter-ion was found to significantly inhibit the growth of studied cell lines in dose-dependent manner with IC50 values from 0.94 to 3.59 μM after 72 h of treatment. According to structure-activity relationships study, the chain length of alkyl substitution on the cation with different anions could play important role towards cytotoxicity of these ionic liquids. Therefore, these results show very promising future for the application of the ionic liquids based on thiabendazole as possible anticancer agents in cancer treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
